Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 5,869 Shares of Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 5,869 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $5.87, for a total value of $34,451.03. Following the completion of the transaction, the insider owned 760,611 shares in the company, valued at $4,464,786.57. The trade was a 0.77% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The shares were sold at an average price of $6.29, for a total value of $24,770.02.
• On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total value of $18,790.44.
• On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total value of $23,005.95.
• On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The shares were sold at an average price of $5.81, for a total value of $76,081.95.
• On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The stock was sold at an average price of $6.03, for a total transaction of $24,952.14.
• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The shares were sold at an average price of $5.95, for a total transaction of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The stock was sold at an average price of $6.32, for a total transaction of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The stock was sold at an average price of $6.54, for a total transaction of $28,560.18.

Clene Trading Up 2.3%

Shares of NASDAQ CLNN opened at $6.28 on Thursday. The firm has a market cap of $64.87 million, a price-to-earnings ratio of -1.85 and a beta of 0.87. The stock has a fifty day simple moving average of $7.88 and a two-hundred day simple moving average of $6.39. Clene Inc. has a 1-year low of $2.28 and a 1-year high of $13.50.

Clene (NASDAQ:CLNN) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. Analysts forecast that Clene Inc. will post -5.19 EPS for the current year.

Hedge Funds Weigh In On Clene

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Scoggin Management LP increased its holdings in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after buying an additional 107,250 shares during the last quarter. Lunt Capital Management Inc. grew its position in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock worth $199,000 after acquiring an additional 21,217 shares in the last quarter. Jane Street Group LLC bought a new position in Clene in the second quarter valued at $47,000. Finally, Jones Financial Companies Lllp purchased a new stake in Clene during the third quarter valued at about $29,000. Hedge funds and other institutional investors own 23.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Benchmark reissued a “buy” rating on shares of Clene in a report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $23.00 target price on shares of Clene in a report on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).